Regel Therapeutics details its proprietary T3 platform and development pipeline on its newly launched website, expands its Board of Directors and announces its Scientific Advisory Board.

The company launches its website with key pipeline information Regel adds industry leader Andrew Schiermeier, Ph.D to its Board of Directors Regel announces its Scientific Advisory Board chaired by Regel Co-Founder Orrin Devinsky, M.D. CAMBRIDGE, Mass. and BERKELEY, Calif., Jan. 27, 2023…

Click here to view original post